Prestige Consumer Cuts Fiscal 2027 Forecast

The company lowered its revenue and adjusted earnings outlook after production variability at Pillar5 affected Clear Eyes supply.

Updated on Nov. 6, 2026 in Consumer Goods

Isometric editorial illustration of stacked plain amber vessels beside a conveyor belt, with one empty crate tipped over, suggesting a gap in product supply. — Prestige Consumer Healthcare lowered its fiscal 2027 revenue and adjusted earnings guidance on November 5, citing Clear Eyes production variability at Pillar5. AI Illustration. Upload story photo >

Prestige Consumer Healthcare reported fiscal second-quarter revenue of $336.307 million, up 22.7% year over year, and lowered its fiscal 2027 revenue and adjusted earnings guidance on November 5. The revision followed recent variability in Clear Eyes production at Pillar5.

Why it matters

The revised outlook reflects reduced expected availability and revenue for Clear Eyes in the second half of fiscal 2027. The company's organic growth outlook was also lowered to roughly flat from 1% to 3%.

Revenue declined 1.6% excluding acquisitions and foreign currency effects, while the Breathe Right and LaCorium acquisitions contributed $65.083 million. The company's adjusted free cash flow target was trimmed to at least $265 million from at least $270 million.

The players

Prestige Consumer Healthcare

Prestige Consumer Healthcare is a consumer healthcare company that markets over-the-counter brands including Clear Eyes and Breathe Right.

The details

Prestige Consumer Healthcare attributed the revision to recent Clear Eyes production variability at Pillar5, which is expected to reduce product availability and revenue in the second half of fiscal 2027. The company also trimmed its adjusted free cash flow target and organic growth outlook.

June 2026: Breathe Right acquisition closed.
July 2026: LaCorium acquisition closed.
September 30, 2026: Fiscal second quarter ended.
November 5, 2026: Company revised fiscal 2027 revenue and EPS forecasts.

Market Landscape

Prestige's guidance revision shows how a single production issue at one site can ripple into company-wide forecasts in the over-the-counter consumer health sector. The company's acquisitions of Breathe Right and LaCorium helped lift reported revenue even as organic sales slipped.

Shoppers who rely on Clear Eyes may see reduced product availability during the second half of fiscal 2027. The revised guidance signals that supply constraints could affect the brand's shelf presence.

The takeaway

Supply disruptions at a single manufacturing site can quickly reshape a consumer health company's full-year outlook. Watching guidance revisions alongside acquisition contributions helps separate organic performance from reported growth.